The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
case-study
Regulatory Expectations for Sterile Filtration Process Control
Read More
case-study
Strategic CMC Development Partnership Enabling Timely Approval and Launch of a Breakthrough Product
Read More
case-study
Partnership with a Canadian Pharma Organization resulted in savings in effort and material cost for time-critical clinical program
Read More
case-study
Process improvements and in-person monitoring help U.S. pharmaceutical company achieve on time for Phase III clinical trials
Read More
Let's move from science to success.
Let’s Talk